• Gastrointestinal
Name No. Patient Profile Purpose
CTRIAL-IE 11-32 Lithium 11-32

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.


  • Gastrointestinal
Name No. Patient Profile Purpose
MK3475-937 (KEYNOTE-937) 19-07

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).


  • Gastrointestinal
Name No. Patient Profile Purpose
SOLSTICE CTRIAL-IE 19-08

Metastatic colorectal cancer (bowel cancer) that is unresectable and not suitable for intensive therapy

The main purpose of the study is to determine if S95005 in combination with bevacizumab is better than capecitabine with bevacizumab for progression free survival in mCRC patients who have not received any treatment for metastatic disease yet and are not suitable for intensive chemotherapy


  • Gastrointestinal
Name No. Patient Profile Purpose
MK7902-002 18-43

This study is for patients with hepatocellular cancer (type of liver cancer) which has spread (metastasised)

To compare the safety and efficacy between the two groups in this study – those treated with Lenvatinb and Pembrolizumab and those treated with Lenvatib alone.


  • Gastrointestinal
Name No. Patient Profile Purpose
KEYNOTE-859 (MK3475-859) 18-30

Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction).

This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy.

Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy.


  • Gastrointestinal
Name No. Patient Profile Purpose
MK3475-811 (KEYNOTE 811) 18-12

Cancer of the oesophagus or gastro-oesophageal junction which has spread (metastasised).

To compare survival between the two groups – those treated with Trastuzumab, chemotherapy and Pembrolizumab and those treated with Trastuzumab, chemotherapy and placebo.


  • Gastrointestinal
Name No. Patient Profile Purpose
COLOSSUS 17-26

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.


  • Gastrointestinal
Name No. Patient Profile Purpose
TRI-LARC 12-38

Cancer of the rectum.

The purpose of this trial is to compare two radiotherapy techniques for treating locally advanced rectal cancer.


  • Gastrointestinal
Name No. Patient Profile Purpose
PDAC Plasma Biomarker 12-31

Pancreatic cancer

The purpose of this trial is to investigate how proteins and genes respond to pancreatic cancer treatment.


  • Gastrointestinal
Name No. Patient Profile Purpose
CRAC Plasma Biomarker 12-27

Colorectal cancer (colon or rectal)

The purpose of this trial is to investigate what proteins and genes are related to the recurrence of colorectal cancer.